
Lupus Nephritis
Uncover what other tests can’t see with AVISE® SLE Monitor, the most advanced autoimmune testing available.
Know more with
AVISE® SLE Monitor
The most advanced assessment available
With a powerful combination of biomarkers that go beyond standard SLE tests, AVISE® SLE Monitor empowers you with the full intel to stay a step ahead of flare ups, regularly monitor disease progression, assess treatment efficacy, and help prevent premature disease advancement and long-term damage.

A more advanced assessment requires a more comprehensive biomarker suite

ES4d is informative even when C3/C4 is unchanged
In a cohort of 124 SLE patients that were followed longitudinally, levels of EC4d fluctuated with disease activity and provided additional information regardless of changes in C3/C4 levels.
Fluctuating C3/C4 Levels
Chronic Low or Normal C3/C4 Levels
Marginal R2 =7.9% (p <0.001)


Superior detection of organ involvement
PC4d: Detect the potential for thrombosis
Our patented CB-CAPs PC4d test has a strong association with a history of thrombosis and risk for ischemic stroke independent of antiphospholipid antibody levels.
Percent of SLE patients with Thrombosis by PC4d status2
30%
PC4d positive
5%
PC4d negative
Anti-C1q: Identify the risk of Lupus Nephritis
Anti-C1q is superior to other biomarkers in association with SELENA-SLEDAI values and lupus nephritis. SLE patients with positive levels are 2X more likely to have renal involvement.
Percent of patients with increased biomarker levels during high disease activity4
Superior detection of changes in disease activity
EC4d: More accurate monitoring
Our proprietary CB-CAPs EC4d test has strong correlation with disease activity and levels decline rapidly with clinical improvement.5
Anti-dsDNA by CIA: Superior accuracy
Chemiluminescence immunoassay (CIA) has expanded dynamic range and demonstrated superior agreement with the Farr assay.1

Superior detection of Lupus Nephritis
EC4d and anti-C1q significantly correlate with decreases in proteinuria observed prospectively—importantly, EC4d had a stronger correlation with uPCR than conventional serum C3/C4.1
Anti-C1q antibodies are significantly associated (OR = 3.2, p < 0.01) with LN independent of demographic and other serological risk factors.1,3
SLE patients who are simultaneously anti-dsDNA, low complement, and anti-C1q positive are most strongly associated (OR = 14.9, p < 0.01) with LN2.3
Clinical Utility: AVISE SLE Monitor Test Report
The AVISE SLE Monitor test should be considered any time the condition of a SLE patient is being assessed.
If the patient is also being monitored with AVISE® HCQ, the AVISE SLE Monitor test report will also include an AVISE HCQ test result page.
References:
- Kao A, Navratil J, Ruffing M, et al. Erythocyte C3d and C4d for Monitoring Disease Activity in Systemic Lupus Erythematosus. Arthritis & Rheumatism. 2010.
- Buyon J, et al. Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus. Lupus Science and Medicine. 2016.
- Merrill J, et al. Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. Lupus Science and Medicine. 2018.
- Mahler M, Bentow C, O’Malley T, et al. Performance Characteristics of Different Anti-Double-Stranded DNA Antibody Assays in the Monitoring of Systemic Lupus Erythematosus. J Immunol Res. 2017;2017:1720902.
- Petri M, Conklin J, Apilado R, et al. Complement C4d Split Products in Combination with Lupus Anticoagulant and Low Complement Associate with Thrombosis in SLE [abstract]. Arthritis Rheumatol. 2018
- Kao A, McBurney C, Sattar A, et al. Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus. Transl Stroke Res 2014; 5(4):510-518.
- Akhter E, Burlingame R, Seaman A, et al. Anti-C1Q antibodies have a higher correlation with flares of lupus nephritis than other serum markers. Lupus. 2012.
- Data on file Exagen, Inc. 2018.